CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Chief Judge Patti B. Saris of the United States District Court for the District of Massachusetts granted Alnylam’s summary judgment motion in an inventorship dispute, holding that Professor Brenda Bass, Distinguished Professor at the University of Utah (“Utah”), is not a co-inventor of certain patents, termed the Tuschl II patents, jointly owned by co-defendants the Max Planck Society (“Max Planck”), University of Massachusetts (“UMass”), Massachusetts Institute of Technology (“MIT”), and the Whitehead Institute for Biomedical Research (“Whitehead”), and exclusively licensed to Alnylam.
Help employers find you! Check out all the jobs and post your resume.
